Clinical trial NCT01572818: Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients
Official title: Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Insulin Resistance
Iron Overload
Keywords: Phlebotomy
Insulin Resistance
Iron Overload
Lead sponsor: Rennes University Hospital
Sponsor class: OTHER
First posted: 2012-04-06
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate efficacy of phlebotomy on insulin sensitivity as evaluated by euglycemic-hyperinsulinic clamp in insulin resistance-associated hepatic iron overload patients.

Detailed description: The main objective of this study is to evaluate in patients with HSD effects of treatment with phlebotomy rules with lifestyle and dietary rules versus lifestyle modifications alone on peripheral insulin resistance (assessed by hyperinsulinemic clamp).

Secondary objectives are:

* to study in all patients with HSD the relationship between the amount of iron intrahepatic and degree of peripheral insulin resistance and liver before therapeutic intervention.
* to study and compare the effects of phlebotomy treatment versus no treatment on:

  * Plasma levels of adipocytokines,
  * Plasma concentrations of inflammatory markers and markers of insulin resistance,
  * The serum ferritin,
  * The post-hepatic clearance of insulin,
  * The surface of the abdominal visceral fat and subcutaneous abdominal.

Eligibility criteria: Inclusion Criteria:

* Age between 18 and 70 years
* Ferritin between 450 and 1000 µg/L
* Hepatic iron overload proved by MRI (CHF \>36 µmol/g)
* Body mass index \> 25 kg/m²
* Fasting glycemia \<1,26 g/L
* HbA1c \< 6,5%
* Signed written and informed consent

Exclusion Criteria:

* Other causes of hyperferritinemia:

  * Inflammatory syndrome (CRP \>10 mg/L) or inflammatory, immune or malignant diseases
  * Hyperferritinemia-cataract syndrome (familial cataract or personal history of cataract before 50 years old)
  * Low ceruloplasmin level
  * Porphyria (cutaneous signs)
  * Haemochromatosis established by the genotype (C282Y homozygous or C282Y/H63D coumpound heterozygous genotypes)
* Contraindication of phlebotomy

  * Haemoglobin \<13,5 g/dL (threshold established by the Etablissement Français du Sang)
  * Heart failure or coronary heart diseases
  * Hepatic failure, renal (GFR \<50mL/min) or respiratory insufficiency (chronic dyspnea)
  * Poor venous system
* Viral, immune, genetic, vascular, malignant or toxic chronic hepatic disease
* Alcohol consumption more than 21 doses per week during 5 years or more
* Type 1 or type 2 diabetes
* Oral anti-diabetic, corticoids or immune suppressor drugs
* Hepatic severe disease
* Claustrophobia, having a pace-maker or intracerebral clips
* Subjects deprived of their liberty by judicial or administrative decision, subjects that are not affiliated to social security or topics exclusion period of a previous study

Primary outcomes:
measure: Glucose Infusion Rate by euglycemic-hyperinsulinic clamp
timeFrame: 6 months
Secondary outcomes:
measure: hepatic parameters
timeFrame: 6 months
measure: inflammation markers
timeFrame: 6 months
measure: Adipokins markers
timeFrame: 6 months
measure: SHBG
timeFrame: 6 months
measure: HOMA-IR
timeFrame: 6 months
measure: Hepatic iron overload (MRI)
timeFrame: 6 months
measure: Abdominal and sub-cutaneous fat surface (MRI)
timeFrame: 6 months
measure: iron parameters
timeFrame: at 6 months
measure: lipid profile
timeFrame: at 6 months
Other outcomes:
Locations:
city: Nantes
country: France
facility: CHU
city: Rennes
country: France
facility: CHU
Study officials:
affiliation: Rennes University Hospital
name: Fabrice BONNET, MD, PHD
role: PRINCIPAL_INVESTIGATOR
affiliation: RennesUniversity Hospital
name: Eric Bellissant, MD, PhD
role: STUDY_CHAIR
References: